ARDRE partners
The ARDRE ancillary network
Small and Mid-sized Enterprise, SMEs, dealing with all aspects of using natural products for improving human health, as well as big pharma, involved in drug screening, drug design and clinical realization are part of the multifaceted ARDRE ancillary network. The primary non-academic organisations are SMEs involved in drug research and/or translational research into ageing and regeneration and big pharmaceutical companies. The ARDRE-DP has various powerful measures to provide an excellent basis for international networking of its PhD students.
Collaborations with the following renowned research institutions exist:
- University of California at Davis (USA)
- Université du Luxembourg (Luxemburg)
- University of Barcelona (Spain)
- University of Birmingham (UK)
- University of Padova (Italy)
- Technical University Dresden (Germany)
- University of Galway (Ireland)
- Max Planck Institute for Heart and Lung Research (Germany)
- University Hospital Ulm (Germany)
- New York University (USA)
- Swiss Federal Institute of Technology Zürich (Switzerland)
- California Institute of Technology (USA)
- Institut de biologie du Developpement de Marseille (France)
- Universidad Pablo de Olavide Sevilla (Spain)
- University of Konstanz (Germany)
- Universite de Rennes 1 (France)
- Friedrich Schiller University of Jena (Germany)
- University of Newcastle upon Tyne (UK)
- German Cancer Research Center (DKFZ) and University of Heidelberg (Germany)
- MUI, Medical University of lnnsbruck (Austria)
The following non-academic commercial partners are also a part of the ARDRE ancillary network:
- VivaCell Biotechnology GmbH (Germany)
- Boehringer Ingelheim Pharma GmbH & Co. KG (Germany)
- Oiflame Cosmetics AB (Sweden)
- AnalytiCon Discovery GmbH (Germany)
- Janssen Pharmaceutica N.V. (Belgium)
- Novartis Institutes for BioMedical Research (Switzerland)
- Bayer AG (Germany)
- Oroboros Instruments GmbH (Austria)
- Smartox Biotechnology (France)
Funding
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847681.
